Compare BridgeBio Pharma Inc (BBIO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Schlumberger NV — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Schlumberger NV trades at $47.68 (market cap $71.08B). The key difference: Schlumberger NV is far larger — about 4.3× BridgeBio Pharma Inc's market cap, and Schlumberger NV pays a 2.48% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SLB | |
|---|---|---|
Market Cap | $16.46B | $71.08B |
Sector | Health | Energy |
52-Week High | $90.17 | $58.01 |
52-Week Low | $44.81 | $31.72 |
Enterprise Value | $18.02B | $79.30B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
SLB trades at $47.36, down 0.84% on the day, with a neutral technical signal. The company reported revenue of $35.71 billion in 2025, with a net income margin of 9.26% and a P/E ratio of 20.86. Recent news includes a major EPC contract win for the Baleine Phase 3 development and a strategic alliance with Liberty Energy for data center infrastructure, highlighting diversification efforts.
The outlook is supported by strong analyst consensus with a $63.00 price target and 84.85% buy ratings, but risks include oil price volatility and a recent dip in profit margins. Earnings have consistently beaten expectations, providing fundamental strength amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
